hVIVO Company
hVIVO, a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. hVIVO changed its name from Retroscreen Virology in April 2015. The business is a plc quoted on the AIM London Stock Exchange (ticker вАШHVOвАЩ).
Total Funding:
$2.6M
Headquarters:
London, England, United Kingdom
Funding Status:
IPO
Employee Number:
501-1000
Estimated Revenue:
$10M to $50M
Number Of Exists:
Series B
Technology:
Data-driven Technologies
Investor Type:
Investor
Founded Date:
1988
Industry:
PharmTech